erlotinib hydrochloride CAS NO.183319-69-9

Anqing World Chemical Co.,Ltd.Mainly responsible for the development of domestic and international business.In 2015,Haikang established the second branch,called Anqing Xuanyu Medical&Technology Co., Ltd, it is an R&D company that selects reliable technology and cooperative research partner for our corporation.

Haikang is committed to R&D,manufacture and sales of chemical raw materials API and intermediates.Meanwhile,we also provide services like product customization,process improvement,achievement transfer, etc. Through years effort,Haikang has made remarkable achievements in the R&D and production of anti-virus,antidiabetic,antineoplastic,beauty and whitening resist oxidation series API and intermediates.The main products are Ganciclovir, Sitagliptin, Vildagliptin, Silodosin and Imatinib API and Intermediates.

To deal with increasingly competition,Haikang adheres to “Customer is First,Technology is Leading,Quality is Life,Honesty for Developing”,and optimizes actively the products and better service to customers.

erlotinib hydrochloride;
ERLOTINIB HCL SALT;
OSI 774;
ERLOTINIB HCL;
Erlotinib HCl;
Tarceva;
Erlotinib (Hydrochloride);
Erlotinib hydrochloride;
N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine hydrochloride;
Erlotonid HCl;
Erlotinib,OS-774;
Erlotinib Hydrochloride;
Erlotinib-d6 HCl

Erlotinib hydrochloride is the hydrochloride of the molecularly targeted drug erlotinib. The U.S. Food and Drug Administration (FDA) has approved erlotinib (Tarceva) combined with gemcitabine as the first-line treatment for locally advanced and metastatic pancreatic cancer . The small molecule compound erlotinib is a receptor tyrosine kinase inhibitor. It inhibits the phosphorylation reaction by competitively binding with adenosine triphosphate in the cell to the catalytic site of the receptor tyrosine kinase, thereby blocking the It has proliferation signal transduction, inhibits the activity of tumor cell ligand-dependent HER-1/EGFR, and achieves the effect of inhibiting tumor cell proliferation. Erlotinib is also another tyrosine kinase inhibitor used in the treatment of NSCLC. The results of the Phase I clinical trial showed that its main toxicity and side effects were dose-dependent rash and diarrhea, and other rare side effects were headache, nausea and vomiting. Erlotinib was used as a second-line anti-tumor drug in the clinical phase II trial, and its efficacy is equivalent to that of the second-line chemotherapy drug docetaxel. Clinical Phase III Randomized Controlled Trial (BR21) [22], mainly for NSCLC patients (locally advanced and distant metastases) after the failure of first-line or second-line chemotherapy. In the study group, 488 cases were treated with 150 mg of erlotinib per day. A total of 243 patients in the control group received a placebo. The results are: median overall survival rate: 6.7 months for the chemicalbook group and 4.7 months for the control group (P<0.001, death rate HR=0.73); 1-year survival rate: 31.2% for the medication group, 21.5% for the control group; median Progression-free time: 9.9 weeks for the medication group and 7.9 weeks for the control group. At the same time, the improvement of the patient's symptoms was more obvious in the erlotinib group. Based on the research results of BR21, several phase III clinical studies have been carried out one after another. The TRIBUTE clinical trial study combined erlotinib with chemotherapy in an attempt to compare whether it has better efficacy in combination with chemotherapy than chemotherapy alone. The treatment group was chemotherapy (carboplatin plus paclitaxel) + erlotinib, and the control group was the same chemotherapy alone. A total of 1059 patients with advanced NSCLC joined the observation. The effective rate of the study results was 21.5% in the study group and 19.3% in the control group; median survival: 10.8 months in the study group and 10.6 months in the control group; time to tumor progression (TTP): 5.1 months in the study group and 5.0 months in the control group . Another TALENT study also compared whether the combination of erlotinib and chemotherapy (Gemcitabine + Cisplatin) can improve the efficacy of chemotherapy. A total of 1172 NSCLC patients were enrolled. The results also did not show that erlotinib can significantly improve the efficacy of chemotherapy.